Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses
Chemopreventive non-steroidal anti-inflammatory drugs (NSAIDs) exhibit diverse pharmacological and biological activities mainly through their inhibitory effect on cyclooxygenase (COX). However, COX-independent mechanisms involving kinase inhibition have been proposed to explain certain therapeutic e...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 2010-07, Vol.638 (1), p.13-20 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 20 |
---|---|
container_issue | 1 |
container_start_page | 13 |
container_title | European journal of pharmacology |
container_volume | 638 |
creator | Fan, Jia-Rong Huang, Ting-Hsiang Wen, Chen-Yu Shen, Tang-Long Li, Tsai-Kun |
description | Chemopreventive non-steroidal anti-inflammatory drugs (NSAIDs) exhibit diverse pharmacological and biological activities mainly through their inhibitory effect on cyclooxygenase (COX). However, COX-independent mechanisms involving kinase inhibition have been proposed to explain certain therapeutic effects of NSAIDs. Here, we explored the potential relationship between chemopreventive NSAIDs and DNA damage responses induced by treatment with topoisomerase-targeting drugs. (1) Sodium salicylate, a non-COX-selective NSAID, was shown to reduce DNA damage-induced RPA and p53 phosphorylation. (2) The formation of enzyme cleavable complexes by topoisomerase-targeting drugs was not affected in the presence of sodium salicylate. (3) The attenuating effect of NSAIDs on the DNA damage responses is COX-2-independent, since COX-2-selective inhibitors failed to inhibit DNA damage-induced phosphorylation of replication protein A (RPA) and p53. (4) This COX-2-independent attenuating effect was mediated through interference of neither nuclear factor kappa B nor extracellular signal-regulated kinase pathways. (5) The activation of ataxia telangiectasia mutated (ATM) kinase and DNA-dependent protein kinase (DNA-PK), two key signal transducers upstream of RPA and p53, was found to be significantly reduced with sodium salicylate treatment. (6) Most importantly, sodium salicylate and other NSAIDs directly inhibited kinase activity of ATM and DNA-PK. The extent of inhibition on the kinase activity also correlated with the degree of attenuation on the DNA damage responses. (7) Unexpectedly, sodium salicylate showed a p53-independent protection effect on topoisomerase-mediated cell killing. Together, our study provides evidence that NSAIDs exhibit a novel COX-independent modulating activity of NSAIDs on the DNA damage responses and it is through inhibition of phosphoinositide 3-kinase-like kinases. |
doi_str_mv | 10.1016/j.ejphar.2010.04.012 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_904487565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299910003183</els_id><sourcerecordid>904487565</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-94f1bcf9e4d9cd6e8c375e1be29ffc26f641b0abcb278925ff8ceab3610419393</originalsourceid><addsrcrecordid>eNqFkc1u1TAUhC1ERW8Lb4CQN4hVLv7LjzdIVaGAVLWLwtpy7OPGt0kc7ASpr8ET45AL7GBh2Rp9M7bPIPSSkj0ltHp72MNh6nTcM5IlIvaEsidoR5taFqSm7CnaEUJFwaSUp-gspQMhpJSsfIZOGRGkqjjZoR93wfplwEn33jz2egaszZzw3MWw3HfY-ghmxn7sfOtnH0YcHJ66kPLyY0hZs4B58eBHnaDo_QPg7ZwzAh6CXX6FzmEKPoUB4ooNYH1WLX5_c4GtHvQ94AhpCmP2PUcnTvcJXhz3c_T16sOXy0_F9e3Hz5cX14URjM-FFI62xkkQVhpbQWN4XQJtgUnnDKtcJWhLdGtaVjf52841BnTLK0oElVzyc_Rmy51i-LZAmtXgk4G-1yOEJSlJhGjqsir_S9ac06Ys6zVTbKSJIaUITk3RDzo-KkrUWps6qK02tdamiFC5tmx7dbxgafNs_ph-95SB10dAJ6N7F_VofPrLsaZinK9B7zYO8uC-e4gqGQ-jga1HZYP_90t-Arfju3Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733185579</pqid></control><display><type>article</type><title>Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses</title><source>MEDLINE</source><source>ScienceDirect Freedom Collection (Elsevier)</source><creator>Fan, Jia-Rong ; Huang, Ting-Hsiang ; Wen, Chen-Yu ; Shen, Tang-Long ; Li, Tsai-Kun</creator><creatorcontrib>Fan, Jia-Rong ; Huang, Ting-Hsiang ; Wen, Chen-Yu ; Shen, Tang-Long ; Li, Tsai-Kun</creatorcontrib><description>Chemopreventive non-steroidal anti-inflammatory drugs (NSAIDs) exhibit diverse pharmacological and biological activities mainly through their inhibitory effect on cyclooxygenase (COX). However, COX-independent mechanisms involving kinase inhibition have been proposed to explain certain therapeutic effects of NSAIDs. Here, we explored the potential relationship between chemopreventive NSAIDs and DNA damage responses induced by treatment with topoisomerase-targeting drugs. (1) Sodium salicylate, a non-COX-selective NSAID, was shown to reduce DNA damage-induced RPA and p53 phosphorylation. (2) The formation of enzyme cleavable complexes by topoisomerase-targeting drugs was not affected in the presence of sodium salicylate. (3) The attenuating effect of NSAIDs on the DNA damage responses is COX-2-independent, since COX-2-selective inhibitors failed to inhibit DNA damage-induced phosphorylation of replication protein A (RPA) and p53. (4) This COX-2-independent attenuating effect was mediated through interference of neither nuclear factor kappa B nor extracellular signal-regulated kinase pathways. (5) The activation of ataxia telangiectasia mutated (ATM) kinase and DNA-dependent protein kinase (DNA-PK), two key signal transducers upstream of RPA and p53, was found to be significantly reduced with sodium salicylate treatment. (6) Most importantly, sodium salicylate and other NSAIDs directly inhibited kinase activity of ATM and DNA-PK. The extent of inhibition on the kinase activity also correlated with the degree of attenuation on the DNA damage responses. (7) Unexpectedly, sodium salicylate showed a p53-independent protection effect on topoisomerase-mediated cell killing. Together, our study provides evidence that NSAIDs exhibit a novel COX-independent modulating activity of NSAIDs on the DNA damage responses and it is through inhibition of phosphoinositide 3-kinase-like kinases.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2010.04.012</identifier><identifier>PMID: 20406630</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Ataxia Telangiectasia Mutated Proteins ; Biological and medical sciences ; Camptothecin - pharmacology ; Cell Cycle Proteins - antagonists & inhibitors ; Cell Cycle Proteins - metabolism ; Cell Death - drug effects ; Cyclooxygenase ; Cyclooxygenase 2 Inhibitors - pharmacology ; DNA Damage - drug effects ; DNA damage response ; DNA Topoisomerases - drug effects ; DNA-Activated Protein Kinase - antagonists & inhibitors ; DNA-Activated Protein Kinase - metabolism ; DNA-Binding Proteins - antagonists & inhibitors ; DNA-Binding Proteins - metabolism ; Drug Interactions ; HCT116 Cells ; Humans ; Medical sciences ; NF-kappa B ; Nuclear factor kappa B ; Pharmacology. Drug treatments ; Phosphoinositide 3-kinase-like kinase ; Phosphorylation - drug effects ; Protein-Serine-Threonine Kinases - antagonists & inhibitors ; Protein-Serine-Threonine Kinases - metabolism ; Replication Protein A - metabolism ; Signal Transduction - drug effects ; Sodium salicylate ; Sodium Salicylate - pharmacology ; Topoisomerase cleavable complex ; Tumor Suppressor Protein p53 - metabolism ; Tumor Suppressor Proteins - antagonists & inhibitors ; Tumor Suppressor Proteins - metabolism</subject><ispartof>European journal of pharmacology, 2010-07, Vol.638 (1), p.13-20</ispartof><rights>2010 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>(c) 2010 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-94f1bcf9e4d9cd6e8c375e1be29ffc26f641b0abcb278925ff8ceab3610419393</citedby><cites>FETCH-LOGICAL-c423t-94f1bcf9e4d9cd6e8c375e1be29ffc26f641b0abcb278925ff8ceab3610419393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2010.04.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22862332$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20406630$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fan, Jia-Rong</creatorcontrib><creatorcontrib>Huang, Ting-Hsiang</creatorcontrib><creatorcontrib>Wen, Chen-Yu</creatorcontrib><creatorcontrib>Shen, Tang-Long</creatorcontrib><creatorcontrib>Li, Tsai-Kun</creatorcontrib><title>Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Chemopreventive non-steroidal anti-inflammatory drugs (NSAIDs) exhibit diverse pharmacological and biological activities mainly through their inhibitory effect on cyclooxygenase (COX). However, COX-independent mechanisms involving kinase inhibition have been proposed to explain certain therapeutic effects of NSAIDs. Here, we explored the potential relationship between chemopreventive NSAIDs and DNA damage responses induced by treatment with topoisomerase-targeting drugs. (1) Sodium salicylate, a non-COX-selective NSAID, was shown to reduce DNA damage-induced RPA and p53 phosphorylation. (2) The formation of enzyme cleavable complexes by topoisomerase-targeting drugs was not affected in the presence of sodium salicylate. (3) The attenuating effect of NSAIDs on the DNA damage responses is COX-2-independent, since COX-2-selective inhibitors failed to inhibit DNA damage-induced phosphorylation of replication protein A (RPA) and p53. (4) This COX-2-independent attenuating effect was mediated through interference of neither nuclear factor kappa B nor extracellular signal-regulated kinase pathways. (5) The activation of ataxia telangiectasia mutated (ATM) kinase and DNA-dependent protein kinase (DNA-PK), two key signal transducers upstream of RPA and p53, was found to be significantly reduced with sodium salicylate treatment. (6) Most importantly, sodium salicylate and other NSAIDs directly inhibited kinase activity of ATM and DNA-PK. The extent of inhibition on the kinase activity also correlated with the degree of attenuation on the DNA damage responses. (7) Unexpectedly, sodium salicylate showed a p53-independent protection effect on topoisomerase-mediated cell killing. Together, our study provides evidence that NSAIDs exhibit a novel COX-independent modulating activity of NSAIDs on the DNA damage responses and it is through inhibition of phosphoinositide 3-kinase-like kinases.</description><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Ataxia Telangiectasia Mutated Proteins</subject><subject>Biological and medical sciences</subject><subject>Camptothecin - pharmacology</subject><subject>Cell Cycle Proteins - antagonists & inhibitors</subject><subject>Cell Cycle Proteins - metabolism</subject><subject>Cell Death - drug effects</subject><subject>Cyclooxygenase</subject><subject>Cyclooxygenase 2 Inhibitors - pharmacology</subject><subject>DNA Damage - drug effects</subject><subject>DNA damage response</subject><subject>DNA Topoisomerases - drug effects</subject><subject>DNA-Activated Protein Kinase - antagonists & inhibitors</subject><subject>DNA-Activated Protein Kinase - metabolism</subject><subject>DNA-Binding Proteins - antagonists & inhibitors</subject><subject>DNA-Binding Proteins - metabolism</subject><subject>Drug Interactions</subject><subject>HCT116 Cells</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>NF-kappa B</subject><subject>Nuclear factor kappa B</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphoinositide 3-kinase-like kinase</subject><subject>Phosphorylation - drug effects</subject><subject>Protein-Serine-Threonine Kinases - antagonists & inhibitors</subject><subject>Protein-Serine-Threonine Kinases - metabolism</subject><subject>Replication Protein A - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Sodium salicylate</subject><subject>Sodium Salicylate - pharmacology</subject><subject>Topoisomerase cleavable complex</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Tumor Suppressor Proteins - antagonists & inhibitors</subject><subject>Tumor Suppressor Proteins - metabolism</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1TAUhC1ERW8Lb4CQN4hVLv7LjzdIVaGAVLWLwtpy7OPGt0kc7ASpr8ET45AL7GBh2Rp9M7bPIPSSkj0ltHp72MNh6nTcM5IlIvaEsidoR5taFqSm7CnaEUJFwaSUp-gspQMhpJSsfIZOGRGkqjjZoR93wfplwEn33jz2egaszZzw3MWw3HfY-ghmxn7sfOtnH0YcHJ66kPLyY0hZs4B58eBHnaDo_QPg7ZwzAh6CXX6FzmEKPoUB4ooNYH1WLX5_c4GtHvQ94AhpCmP2PUcnTvcJXhz3c_T16sOXy0_F9e3Hz5cX14URjM-FFI62xkkQVhpbQWN4XQJtgUnnDKtcJWhLdGtaVjf52841BnTLK0oElVzyc_Rmy51i-LZAmtXgk4G-1yOEJSlJhGjqsir_S9ac06Ys6zVTbKSJIaUITk3RDzo-KkrUWps6qK02tdamiFC5tmx7dbxgafNs_ph-95SB10dAJ6N7F_VofPrLsaZinK9B7zYO8uC-e4gqGQ-jga1HZYP_90t-Arfju3Q</recordid><startdate>20100725</startdate><enddate>20100725</enddate><creator>Fan, Jia-Rong</creator><creator>Huang, Ting-Hsiang</creator><creator>Wen, Chen-Yu</creator><creator>Shen, Tang-Long</creator><creator>Li, Tsai-Kun</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TM</scope></search><sort><creationdate>20100725</creationdate><title>Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses</title><author>Fan, Jia-Rong ; Huang, Ting-Hsiang ; Wen, Chen-Yu ; Shen, Tang-Long ; Li, Tsai-Kun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-94f1bcf9e4d9cd6e8c375e1be29ffc26f641b0abcb278925ff8ceab3610419393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Ataxia Telangiectasia Mutated Proteins</topic><topic>Biological and medical sciences</topic><topic>Camptothecin - pharmacology</topic><topic>Cell Cycle Proteins - antagonists & inhibitors</topic><topic>Cell Cycle Proteins - metabolism</topic><topic>Cell Death - drug effects</topic><topic>Cyclooxygenase</topic><topic>Cyclooxygenase 2 Inhibitors - pharmacology</topic><topic>DNA Damage - drug effects</topic><topic>DNA damage response</topic><topic>DNA Topoisomerases - drug effects</topic><topic>DNA-Activated Protein Kinase - antagonists & inhibitors</topic><topic>DNA-Activated Protein Kinase - metabolism</topic><topic>DNA-Binding Proteins - antagonists & inhibitors</topic><topic>DNA-Binding Proteins - metabolism</topic><topic>Drug Interactions</topic><topic>HCT116 Cells</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>NF-kappa B</topic><topic>Nuclear factor kappa B</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphoinositide 3-kinase-like kinase</topic><topic>Phosphorylation - drug effects</topic><topic>Protein-Serine-Threonine Kinases - antagonists & inhibitors</topic><topic>Protein-Serine-Threonine Kinases - metabolism</topic><topic>Replication Protein A - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Sodium salicylate</topic><topic>Sodium Salicylate - pharmacology</topic><topic>Topoisomerase cleavable complex</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Tumor Suppressor Proteins - antagonists & inhibitors</topic><topic>Tumor Suppressor Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fan, Jia-Rong</creatorcontrib><creatorcontrib>Huang, Ting-Hsiang</creatorcontrib><creatorcontrib>Wen, Chen-Yu</creatorcontrib><creatorcontrib>Shen, Tang-Long</creatorcontrib><creatorcontrib>Li, Tsai-Kun</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Nucleic Acids Abstracts</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fan, Jia-Rong</au><au>Huang, Ting-Hsiang</au><au>Wen, Chen-Yu</au><au>Shen, Tang-Long</au><au>Li, Tsai-Kun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2010-07-25</date><risdate>2010</risdate><volume>638</volume><issue>1</issue><spage>13</spage><epage>20</epage><pages>13-20</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>Chemopreventive non-steroidal anti-inflammatory drugs (NSAIDs) exhibit diverse pharmacological and biological activities mainly through their inhibitory effect on cyclooxygenase (COX). However, COX-independent mechanisms involving kinase inhibition have been proposed to explain certain therapeutic effects of NSAIDs. Here, we explored the potential relationship between chemopreventive NSAIDs and DNA damage responses induced by treatment with topoisomerase-targeting drugs. (1) Sodium salicylate, a non-COX-selective NSAID, was shown to reduce DNA damage-induced RPA and p53 phosphorylation. (2) The formation of enzyme cleavable complexes by topoisomerase-targeting drugs was not affected in the presence of sodium salicylate. (3) The attenuating effect of NSAIDs on the DNA damage responses is COX-2-independent, since COX-2-selective inhibitors failed to inhibit DNA damage-induced phosphorylation of replication protein A (RPA) and p53. (4) This COX-2-independent attenuating effect was mediated through interference of neither nuclear factor kappa B nor extracellular signal-regulated kinase pathways. (5) The activation of ataxia telangiectasia mutated (ATM) kinase and DNA-dependent protein kinase (DNA-PK), two key signal transducers upstream of RPA and p53, was found to be significantly reduced with sodium salicylate treatment. (6) Most importantly, sodium salicylate and other NSAIDs directly inhibited kinase activity of ATM and DNA-PK. The extent of inhibition on the kinase activity also correlated with the degree of attenuation on the DNA damage responses. (7) Unexpectedly, sodium salicylate showed a p53-independent protection effect on topoisomerase-mediated cell killing. Together, our study provides evidence that NSAIDs exhibit a novel COX-independent modulating activity of NSAIDs on the DNA damage responses and it is through inhibition of phosphoinositide 3-kinase-like kinases.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>20406630</pmid><doi>10.1016/j.ejphar.2010.04.012</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 2010-07, Vol.638 (1), p.13-20 |
issn | 0014-2999 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_904487565 |
source | MEDLINE; ScienceDirect Freedom Collection (Elsevier) |
subjects | Anti-Inflammatory Agents, Non-Steroidal - pharmacology Ataxia Telangiectasia Mutated Proteins Biological and medical sciences Camptothecin - pharmacology Cell Cycle Proteins - antagonists & inhibitors Cell Cycle Proteins - metabolism Cell Death - drug effects Cyclooxygenase Cyclooxygenase 2 Inhibitors - pharmacology DNA Damage - drug effects DNA damage response DNA Topoisomerases - drug effects DNA-Activated Protein Kinase - antagonists & inhibitors DNA-Activated Protein Kinase - metabolism DNA-Binding Proteins - antagonists & inhibitors DNA-Binding Proteins - metabolism Drug Interactions HCT116 Cells Humans Medical sciences NF-kappa B Nuclear factor kappa B Pharmacology. Drug treatments Phosphoinositide 3-kinase-like kinase Phosphorylation - drug effects Protein-Serine-Threonine Kinases - antagonists & inhibitors Protein-Serine-Threonine Kinases - metabolism Replication Protein A - metabolism Signal Transduction - drug effects Sodium salicylate Sodium Salicylate - pharmacology Topoisomerase cleavable complex Tumor Suppressor Protein p53 - metabolism Tumor Suppressor Proteins - antagonists & inhibitors Tumor Suppressor Proteins - metabolism |
title | Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A27%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sodium%20salicylate%20acts%20through%20direct%20inhibition%20of%20phosphoinositide%203-kinase-like%20kinases%20to%20modulate%20topoisomerase-mediated%20DNA%20damage%20responses&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Fan,%20Jia-Rong&rft.date=2010-07-25&rft.volume=638&rft.issue=1&rft.spage=13&rft.epage=20&rft.pages=13-20&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/j.ejphar.2010.04.012&rft_dat=%3Cproquest_cross%3E904487565%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733185579&rft_id=info:pmid/20406630&rft_els_id=S0014299910003183&rfr_iscdi=true |